arcoris bio, a Swiss life science research tools and in vitro diagnostics company, has secured €6.7 million (CHF 6.3 million) in an oversubscribed Seed financing round to advance the development and commercialisation of its breakthrough MUSE biomarker detection platform.
The round was co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and both existing and new private investors.
“Attracting two lead investors with deep industry expertise is a strong validation of our technical and business strategy. This support empowers us in our mission of transforming biomarker detection and digital pathology,” commented Simon Restrepo, co-founder and CSO arcoris bio.
In 2025, European startups developing life-science research tools, diagnostics, and biomarker-detection technologies have continued to attract early-stage investment.
In Sweden, Epigenica AB secured €1.8 million to expand its high-throughput epigenetic screening tools and accelerate international commercialisation.
In France, MSInsight closed a €1.6 million Seed round to advance MSIcare, its AI-powered diagnostic software for detecting microsatellite instability cancers.
In the UK, Sava Technologies raised €16.6 million (Series A) to accelerate approval and launch of its wearable molecular biosensor platform capable of real-time multi-biomarker monitoring.
Against this backdrop, arcoris bio’s €6.7 million Seed financing positions the Swiss firm within a broader European movement to industrialise and scale next-generation biomarker and diagnostic technologies.
Its MUSE platform, focusing on multiplex biomarker detection and digital pathology, reflects a shared trend toward enabling higher-sensitivity, data-rich diagnostic solutions.
While comparable rounds in Sweden and France remain smaller, the company’s Swiss base and strong venture backing place it among the more substantial early-stage players in this fast-developing European diagnostics tools landscape.
Matyas Vegh, CEO arcoris bio, added: “Securing this financing marks a major milestone for arcoris bio. In a challenging market, we are grateful for the trust our investors have placed in our vision. Their support empowers us to bring our innovations to market faster, strengthen our operations, and scale to meet growing industry demand.”
Founded in 2022 by Simon Restrepo and Scott E. Fraser, together with entrepreneur H. Kaspar Binz, arcoris bio develops tech for biomarker detection in research and diagnostics. Its flagship MUSE platform provides universal, programmable signal amplification to enable highly sensitive and multiplex assays and advance digital pathology.
MUSE enables researchers to detect multiple biomarkers simultaneously with “unprecedented” ease and sensitivity. By allowing the measurement of several difficult-to-detect biomarkers within a single sample at higher throughput.
Andreas Jenne, Investment Director at Ventura Ace, said: “We have been impressed by the arcoris bio team’s vision and early traction with industry partners. We believe MUSE represents a truly enabling technology for digital pathology.”
The financing will enable arcoris bio to industrialise MUSE and expand strategic partnerships and launch new products.
“arcoris bio’s MUSE technology fills a critical gap in the market to enable better diagnostics and applications like drug discovery or precision medicine. Its universal applicability is particularly exciting – MUSE acts like a molecular GPU, amplifying the capabilities of existing biomarker platforms and opening new paths for innovation,” highlighted Benedikt Klaes, Senior Investment Manager at ZEISS Ventures.
Read the orginal article: https://www.eu-startups.com/2025/11/schlieren-based-life-science-startup-arcoris-bio-lands-e6-7-million-to-advance-biomarker-detection-platform/
